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Abstract
Background: In this time of rapidly expanding mass drug administration (MDA) coverage and the new commitments
for soil-transmitted helminth (STH) control, it is essential that resources are allocated in an efficient manner to have the
greatest impact. However, many questions remain regarding how best to deliver STH treatment programmes; these
include which age-groups should be targeted and how often. To perform further analyses to investigate what the most
cost-effective control strategies are in different settings, accurate cost data for targeting different age groups at different
treatment frequencies (in a range of settings) are essential.
Methods: Using the electronic databases PubMed, MEDLINE, and ISI Web of Knowledge, we perform a systematic
review of costing studies and cost-effectiveness evaluations for potential STH treatment strategies. We use this review
to highlight research gaps and outline the key future research needs.
Results: We identified 29 studies reporting costs of STH treatment and 17 studies that investigated its cost-effectiveness.
The majority of these pertained to programmes only targeting school-aged children (SAC), with relatively few studies
investigating alternative preventive chemotherapy (PCT) treatment strategies. The methods of cost data collection,
analysis and reporting were highly variable among the different studies. Only four of the costing studies were found
to have high applicability for use in forthcoming economic evaluations. There are also very few studies quantifying the
costs of increasing the treatment frequency.
Conclusions: The absence of cost data and inconsistencies in the collection and analysis methods constitutes a major
research gap for STH control. Detailed and accurate costs of targeting different age groups or increasing treatment
frequency will be essential to formulate cost-effective public health policy. Defining the most cost-effective control
strategies in different settings is of high significance during this period of expanding MDA coverage and new resource
commitments for STH control.
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Review
The primary control strategy for soil-transmitted hel-
minths (STH) is regular periodic mass drug administration
(MDA), also called preventive chemotherapy (PCT), tar-
geting Pre-School Aged Children (Pre-SAC) and School
Aged Children (SAC) [1, 2]. These control programmes
originally depended on vertical programs in which mobile
teams visited schools or communities to distribute the
drugs [3, 4]. Nowadays, they are predominantly centred on
school-based delivery systems, utilising teachers and other
school officials [3, 4]. This delivery method enables the
programmes to be linked in to the school educational
system [3], which has been shown to be both highly
cost-effective, and an effective method to reach children in
poor rural areas [3, 4].
The World Health Organization (WHO) recommends
that MDA programmes prioritise SAC, but also recom-
mends the treatment of Pre-SAC, women of child-
bearing age, and adults in certain high risk occupations
(such as tea-pickers and miners) [1]. In the majority of
endemic areas, treatment is given annually, but in areas
of intense transmission (defined as a prevalence of any
STH greater than 50 % in SAC), the WHO recommends
that the treatment frequency is increased to at least
twice a year (depending on resource availability) [1]. In
areas where lymphatic filariasis (LF) is endemic, the
whole community may be treated through LF control
programmes.
There is currently a period of intensifying MDA cover-
age and new resource commitments for STH control
[5, 6, 7]. The WHO and the London declaration on
NTDs have set goals to scale up MDA, so that by 2020,
75 % of the Pre-SAC and SAC in need, will be treated
regularly [6, 7]. However, many questions remain regar-
ding how best to deliver STH treatment programmes to
achieve the greatest impact; these include which age-
groups should be targeted and how often.
Mathematical models have illustrated that the
optimum target age-group is highly dependent on the
age distribution of the different STH species [8–10]. For
instance, in areas with a medium-high prevalence of
hookworm (for which unlike the other STHs the infec-
tion intensity peaks in adulthood as opposed to child-
hood/adolescence [11–14]) it will likely be necessary to
expand treatment to include adults; particularly in the
context of breaking transmission [8–10]. Consequently,
the optimum treatment strategy will be highly specific to
the local epidemiology.
To perform further analyses to investigate what the
most cost-effective control strategies are in different set-
tings, accurate cost data for targeting different age
groups at different treatment frequencies (in a range of
Fig. 1 Decision tree outlining the inclusion and exclusion of the identified studies; * Several studies reported both costs and cost-effectiveness es-
timates. A PRISMA checklist is provided in Additional file 2
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settings) are essential. This will be crucial to inform the
most efficient use of the expanding resources for STH
control [5].
In this paper, we identify, summarise and analyse
the range of costing studies and cost-effectiveness
analyses which have been performed for the different
potential STH treatment strategies. We then outline
the crucial gaps in knowledge which are essential to
evaluate changes in strategies beyond the current
policies.
Literature search
Systematic searches were performed in October 2014
using the electronic databases PubMed, MEDLINE, and
ISI Web of Knowledge, using the possible variants of
the terms “Soil-transmitted helminths (including vari-
ants on helminth and individual species names), cost(s),
cost analysis, economics, economic evaluation, cost
benefit, cost-effectiveness” (see Additional files 1 and
2). We imposed no language or date restrictions and
the retrieved studies were searched for articles that
were not identified in our database searches. Attempts
were made to access reports/policy documents not in-
cluded in the electronic databases. The literature selec-
tion process is outlined in Fig. 1. All papers that
provided cost estimates for the delivery of STH treat-
ment were considered relevant, even if they did not
fully satisfy the criteria of a costing study [15]. The
identified studies containing costs were stratified by the
target age group, method of delivery and treatment
frequency.
The costing studies were grouped into three categor-
ies, low, medium and high (Table 1), reflecting their
applicability for use in necessary forthcoming eco-
nomic evaluations of alternative STH treatment strat-
egies. This grouping was based on three factors; 1)
whether the cost year and currency exchange rates
were clearly stated, 2) economic costs collected, and 3)
detailed itemised costs reported for the STH control
component of the programme (i.e. no major costs
sources were excluded). Those that provided/did all
three were grouped into high, two into medium, and
only one or none into low.
Results
Reported costs of STH treatment
We identified 29 studies that reported costs associated
with treatment for STH control (Table 1). A summary
of the studies is presented in Table 1 (broken down by
the primary distribution method, age-groups targeted,
treatment frequency, the economic features of the
study, and the results). The majority of studies (18 of
29 (62 %)) were judged to have a low applicability for
use in upcoming economic evaluations. Many of these
were macro-costings of the financial costs (Box 1),
which do not account for several of the key aspects of
the treatment programmes (such as the economic
value of the time volunteered by teachers/community
drug distributors (CDDs) and donated items). Further-
more, several of the reported costs were artificially low
because they did not include the costs of their UK-
based coordinating centre [16, 17] or only collected
data at certain programmatic levels (often not ac-
counting for the costs borne at the national level)
[18]. This must be taken into account when compar-
ing the reported costs between different studies, or
when using the data for subsequent cost-effectiveness
analysis.
Box 1: Glossary
Economic costs: These include estimates of the monetary value of
goods/services for which there is no financial transaction or when the
price of a specific good does not reflect the cost of using it productively
elsewhere. Examples of resources which have no financial costs but do
have important economic costs are the ‘free’ use of building space
provided by Ministries of Health, and the time devoted to MDA by
community drug distributors (CDDs) and teachers. Economic costs are
important when considering issues related to the sustainability and
replicability of interventions.
Economies of scale: The reduction in the average cost per unit
resulting from increased production/output: in this case the
reduction in the cost per treatment as a result of increasing the
number treated.
Economies of scope: The reduction in the average cost per unit
resulting from producing two or more products at once: in this
case the reduction in the cost per treatment, when delivering
more than one intervention at once (i.e. integrated control
programmes).
Financial costs: Those were a monetary transaction has taken place for
the purchase of a resource.
Fixed costs: Costs that are not dependent on the amount of
output: in this case costs that are not dependent on the number
treated.
Macro-costing: Macro-costings (also known as gross costing or
top-down costing) identify cost components at a highly
aggregated level, often only allocating a total budget to specific
programme activities.
Micro-costing: Micro-costing studies (also known as down-up
costing) collect detailed data on resources utilized and the value of
those resources.
Perspective: The perspective of the analysis determines which
costs are included i.e. the patients, service providers or the society
as a whole.
Sensitivity analysis: A sensitivity analysis is a repeat of the primary
analysis, substituting alternative decisions or ranges of values for
decisions that were arbitrary or unclear.
Variable costs: Costs which vary in proportion to the quantity of
output: in this case costs that are dependent on the number
treated.
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Table 1 Overview of the identified costs
Study Country Target of
intervention
Primary
distribution method
Age-groups targeted Treatment
frequency
Perspective
explicitly stated
Year of
price
Currency Economic costs
collected
Costs
itemised
Results
High
[24] Uganda STH and
Schistosomiasis
School-based SAC Annual Y (Service
provider)
2005 US$ Y Y The overall economic cost
per child treated in the six
districts was US$0.54, which
ranged between the districts
from US$0.41 to US$0.91
(delivery costs: US$0.19–0.69).
The overall financial cost per
child treated was US$0.39.
[25] Haiti STH and
Lymphatic
filariasis
Combination Mass treatment (all
persons greater than
two years of age)
Annual Y (Service
provider)
2008–2009 US$ Y Y The economic cost was
US$0.64 per person treated,
which included the value of
the donated drugs. The
programme cost (which
excluded the value of the
donated drugs) was US$0.42
per person treated.
[26] Niger STH and
Schistosomiasis
Combination SAC and targeted
adults
Annual N 2005 US$ Y Y The total economic
delivery cost of the school-
based and community-
based treatment was US$0.76,
and US$0.46
respectively. Including only
the programme costs and
the values change to
US$0.47 and US$0.41
respectively. The average
drug (albendazole and
praziquantel) cost was
US$0.28 per treatment; not
clear which results
included the drugs costs.
[27] Niger STH,
Schistosomiasis,
Lymphatic
filariasis, and
Trachoma
Combination SAC and adults (not
clear if Pre-SAC were
treated)
Annual N 2009 US$ Y Y The average economic cost
of integrated preventive
chemotherapy was US$0.19
(excluding drug costs). The
average financial cost per
treatment of the vertical
schistosomiasis and STH
programme (before the NTD
programmes integrated) was
US$0.10.
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Table 1 Overview of the identified costs (Continued)
Medium
[19] Lao PDR STH within an
immunisation
and vitamin A
supplementation
campaign
Child Health Days Pre SAC and women
of child-bearing age
(SAC were targeted
though the national
deworming
campaign)
Annual N 2009 US$ Y Y The incremental cost of
adding deworming into the
national immunisation
campaign was US$0.03 per
treatment (delivery costs:
US$0.007). This is compared
to US$0.23 per treatment for
the vertical national school-
based deworming campaign
(targeting SAC).
[20] Nigeria STH,
Schistosomiasis,
Lymphatic
filariasis, and
Onchocerciasis
Community drug
distributers (CDDs)
SAC for praziquantel
and SAC and adults
for ivermectin/
albendazole
Annual Y (Service
provider)
2008–2009 US$ N Y In 2008, eight local
government areas received a
single round of ivermectin
and albendazole followed at
least one week later by
praziquantel to SAC. The
following year, a single round
of triple drug administration
was given. When using the
latter the programmatic costs
for MDA (not including drug
and overhead costs), were
reduced by 41.1 % (from
US$0.078 to US$0.046 per
treatment).
[22] Ethiopia STH Child Health Days Pre-SAC One round N 2006 US$ Y Partial The average cost per child
reached by the Child Health
Day programme was US$0.56
(per round) of which
deworming was estimated to
represent 29 % of the cost
(US$0.162).
[23] Uganda STH within an
vitamin A
supplementation
campaign
Child Health Days SAC and Pre-SAC One round Y (Service
provider)
2010 US$ Y Partial# The average cost per child
reached by the Child Health
Day programme was US$0.22
(per round) – including the
cost of vitamin A.
# Although detailed itemised
costs were provided they
pertained to the Child Health
Day programme as a whole
(the purpose of that study)
and not the deworming arm.
[21] Based on
data from
Montserrat
STH Mobile teams Mass treatment Not
applicable
Y (Service
provider)
1988 US$ N Y Presented in a cost menu.
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Table 1 Overview of the identified costs (Continued)
[17] Tanzania STH School-based SAC One round Y (Service
provider)
1996 US$ Y Partial† See [16]
[16] Ghana and
Tanzania
STH School-based SAC One round Y (Service
provider)
1996 US$ Y Partial† The economic cost per
treatment in Ghana, and
Tanzania was US$0.27, and
US$0.26 (delivery: US$0.07,
and US$0.06), respectively.
The financial cost per person
treated in Ghana, and
Tanzania was US$0.24, and
US$0.023 (delivery: US$0.04,
and US$0.03), respectively.
† Note that the results are
artificially low because they
did not include the external
costs of the UK-based
coordinating centre [39].
Low
[37] Seychelles STH and other
intestinal
parasitic
infections
Schools and
(crèches for 3–5
year olds)
SAC and Pre-SAC (3–
5 year olds)
Four
monthly
N 1993–1994 US$ N Y The financial cost of the
programme in 1994 was
estimated to be US$0.40 per
person treated; unclear if the
start-up costs from 1993 were
included or if this is a cost
per round or per year.
[29] India STH (primarily
Ascaris)
Mobile teams Pre-SAC Biannual
(six
monthly)
Y (Patient) 1995–1997 Indian
Rupees
(₹)
N N The incremental financial cost
of treating 5,000 Pre-SAC with
six monthly albendazole for
two years was ₹122,091
(including the drug cost
of ₹20 per dose).
[30] Vietnam STH (within a
weekly iron-folic
acid supplemen-
tation campaign)
Village health
workers
Non-pregnant
women of child-
bearing age
four
monthly in
the first
year and
six monthly
thereafter
Partial 2010 US$ N Partial The yearly financial cost of
the programme was US$0.76
per woman treated; including
the cost of weekly iron
supplementation.
[74] Egypt STH,
Schistosomiasis
and other
intestinal
parasitic
infections
Mobile teams SAC Annual N 2000 US$ N Partial The incremental financial cost
of STH control was US$0.07
per treatment (delivery costs:
US$0.03), when integrated
into the national
schistosomiasis control
programme.
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Table 1 Overview of the identified costs (Continued)
[33] Burundi STH,
Schistosomiasis
and other
intestinal
parasitic
infections
Mobile teams (via
the school)
SAC (selective
treatment)
Annual N 1984–1992 US$ N Partial The financial cost per person
protected in 1984–1985,
1989–1990, and 1991–1992
was US$2.7, US$1.2, and
US$0.70, respectively. The
reported costs per treatment
related to only
schistosomiasis.
[75] Burkina
Faso
STH and
Schistosomiasis
Combination SAC One round N 2004–2005 US$ N Y The financial cost per child
treated was US$0.308 for the
school-based component and
US$0.33 for the community-
based component (delivery:
US$0.084, US$0.107
respectively).
[39] Based on
data from
Tanzania
STH and
Schistosomiasis
School-based SAC Not
applicable
N Not clear US$ N Y Presented in a cost menu [39].
[31] Nigeria Ascaris Mobile teams Varied: A) selective
treatment (treating
the 20 % most heavily
infected), B) targeted
treatment to Pre-SAC
and SAC and C) mass
treatment to all (ex
cluding <1 and preg
nant women)
Three
monthly
N 1989 Naira N Partial The total financial costs (and
delivery costs) were;
A) Selective treatment: 2,491
(12,414),
B) Targeted treatment: 3,956
(3,550),
C) Mass treatment: 4,701
(3,809).
(Total costs are shown as it is
misleading to compare the
cost per treatment for a
selective treatment strategy
to that of mass/targeted
treatment.)
[18] Uganda STH School-based SAC Annual Y (Service
provider)
2004 US$ N Partial‡ The estimated financial cost
per treatment in the four
districts ranged from US$0.063
to S$0.105 (delivery costs:
US$0.04 to US$0.08). ‡ These
cost estimates do not include
the start-up costs or those
incurred at the central level.
[32] Bangladesh STH Mobile teams First dose mass (i.e.
children and
household members)
other doses just
children (2–8 years
old)
Varied: See
legend
(Treatment
frequency
Note 1)
Y (Service
provider)
Not clear Takas (৳) N Partial Project cost per household:
A) ৳301
B) ৳1,897
C) ৳332
D) ৳1,909
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Table 1 Overview of the identified costs (Continued)
[28] Nepal STH within an
vitamin A
supplementation
campaign
Child Health Days Pre-SAC Biannual NA NA US$ NA NA An additional US$80,000 (4 %
of the total cost of the
vitamin A campaign) covered
the cost of biannual
deworming).
[62] Zanzibar STH and
Schistosomiasis
School-based
(“sibling
approach*”)
Non-enrolled SAC One round N 2000 US$ N N The costs linked to drug
transport, training and drug
administration were not
increased by the inclusion of
non-enrolled children.
Therefore, the additional
financial cost of including
non-enrolled SAC using the
sibling approach” consisted
only of the extra drugs
treatments needed. It was
noted that a negligible
additional cost
may be incurred for storage
of leftover drugs.
*Enrolled children invited tell
parents, siblings and friends of
school-age when the next
deworming day is.
[76] Myanmar STH School-based SAC One round N Not clear US$ N Y A crude calculation estimated
that the financial cost per
treatment was approximately
US$0.05 (delivery: US$0.03).
[77] Vietnam STH School-based SAC Annual N Not clear US$ N Y The financial costs per
treatment in 2000–2001,
2002–2003, and 2005–2006
were US$0.71, US$0.11, and
US$0.03 (delivery: US$0.683,
US$0.0857 and US$0.0128)
respectively.
[78] Yemen STH and
Schistosomiasis
Combination
(school-based for
SAC and CDDs/
health workers for
adults and non-
enrolled SAC)
SAC and adults Annual N 2008–2009 US$ N Y The financial cost per person
treated in 2008, and 2009
was US$0.79, and US$0.66
(delivery: US$0.44 and
US$0.37), respectively.
[36] Lao PDR STH School-based SAC Biannual N 2007 US$ N Y In the provinces treating
twice a year the financial cost
(capital costs not annualised)
was US$0.23 per child per
year, while in provinces
treating once a year the cost
was US$0.17 per child per year.
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Table 1 Overview of the identified costs (Continued)
[35] Cambodia STH School-based SAC Biannual N 2003–2004 US$ N Y The financial cost per
treatment in 2003 and 2004
was US$0.122, and US$0.057
(delivery: US$0.096 and
US$0.033), respectively.
[34] Notional STH and
Schistosomiasis
Mobile teams (via
the school)
SAC Annual N Not clear US$ N N Treating for ten years would
cost between US$8 and
US$18 per child (US$0.8-
US$1.8 per year). (Assumes
that four treatments of
praziquantel and eight of
albendazole are given in the
ten year period.
The costing studies were grouped into three categories, low, medium and high, reflecting their applicability for use in forthcoming economic evaluations. This grouping was based on three factors; 1) whether the cost
year and currency exchange rates were clearly stated, 2) economic costs collected, and 3) detailed itemised costs reported for the STH control component of the programme (i.e. no major costs sources were
excluded). Those that provided/did all three were grouped into high, two into medium, and only one or none into low. CDDs; Community drug distributers, Pre-SAC; Pre-school aged children, SAC; School aged children.
School-based delivery systems were defined as those utilising teachers and other school officials (not just distributing the drugs at the school NA: Not available. Treatment frequency Note 1: Varied; A) Chemotherapy to all
household members at the start of the study, B) same as Group A, but with regular health education, C) Chemotherapy to all household members and subsequent six monthly chemotherapy to all children, D) same as Group
C but also with regular health education
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Seven studies were found to have medium [16, 17, 19–23]
and only four high [24–27] applicability for the use in
economic evaluations. It should be noted that the more
in-depth costing studies [24–27] – which also collected
economic costs – reported notably higher MDA delivery
costs (Table 1).
The method of cost data collection, analysis and
reporting was highly variable among the different stud-
ies, with many not providing itemised costs stratified by
programme activities (Table 1). Several studies reported
costs for programmes that were not targeting STH alone
making it difficult to separate out the incremental costs
for only treating STH. This adds notable complexity to
comparing the costs of different treatment strategies.
Furthermore, in many cases the cost year/currency
exchange rates were not explicitly stated, making it
problematic to adjust the results of the different studies
to account for inflation, allowing valid comparison. These
issues are discussed more in the research needs section
below (Cost data collection and analysis methods).
Due to the inconsistencies in both the collection and
analysis methods, as well as the potential differences
between different countries/health systems, it was not
possible to draw firm conclusions regarding the costs of
the different treatment strategies. However, looking at
the number of studies stratified by the target age group,
method of distribution, and treatment frequency, reveals
some important insights regarding the current gaps in
the literature (Fig. 2).
Target population and method of distribution
The clear majority of the identified costing studies were
related to programmes targeting SAC through the school
system (Fig. 2). The older studies were more likely to
pertain to the use of mobile teams (Fig. 3). However, this
method has gradually been replaced by school or
community-based delivery systems (Fig. 3). In Africa, a
combination strategy was often used, using both the
school system to reach enrolled SAC, and CDDs/health
workers to reach un-enrolled SAC and/or other age
groups in the community.
The three studies identified for programmes targeting
only Pre-SAC integrated their distribution either into
Child Health Days [22, 28] or used mobile teams [29].
Two studies were identified that investigated the cost of
treating women of reproductive age within existing im-
munisation and vitamin A or iron supplementation cam-
paigns [19, 30]. These studies either integrated their
distribution into Child Health Days (also targeting Pre-
SAC) [19] or used village health workers [30].
Only 11 studies were found which reported costs per-
taining to programmes targeting more than one age
group (Pre-SAC, SAC and adults) (Fig. 2). Nine studies
reported costs for programmes which included the treat-
ment of adults. However, these were either for pro-
grammes integrated with LF control [20, 25, 27],
programmes targeting only specific groups of adults [19,
26, 30] or programmes based on the use of mobile teams
to distribute the drugs [21, 31, 32]. This is important as
Fig. 2 The number of identified costs for STH treatment stratified by the target age group and the method of distribution. Pre-SAC; Pre-school
aged children, SAC; School aged children. School-based delivery systems were defined as those utilising teachers and other school officials (not
just distributing the drugs at the school). A combination strategy was defined as using both the school system and community drug distributers
(CDDs). Some studies were counted more than once, as the target population was varied within the study. * Targeted adults (such as those in at
risk occupations); ǂ Programme also targeting lymphatic filariasis (LF)
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the treatment of adults will be essential in many areas in
order to break transmission [8–10].
Two studies reported the costs of selective treatment,
where people were screened and only treated if infected
or heavily infected [31, 33]. Even though this approach
uses less drugs than age-targeted or mass treatment, the
requirement of having to screen for infection before
treatment results in the programme being relatively
costly; Holland et al. [31] found that selective treatment
was three times more expensive than targeted control,
although it should be noted that both arms of the study
used mobile teams. This is supported by a theoretical
analysis of helminth control (not specific to STH) pre-
sented by Warren et al. [34], which found that selective
treatment was both less effective and more costly then
mass and targeted treatment strategies. However, it
should be noted that both of these studies pertained to
the use of mobile teams (which now have mostly been
replaced by other delivery systems (Fig. 3)). Though
these findings are very likely to be robust within the
current school/community-based delivery systems, se-
lective treatment may need to be reassessed if new and
more rapid diagnostics are developed.
Treatment frequency
The majority of the studies related to the use of an an-
nual treatment strategy or just investigated one treat-
ment round (Fig. 4). Only two studies were found which
reported the costs associated with biannual treatment
within a school-based programme [35, 36]; however,
these only reported financial costs, and how increasing
the treatment frequency may influence the economic
costs (Box 1) has not been investigated. The handful of
costing studies found for higher treatment frequencies
used mobile teams (which are now rarely used (Fig. 3))
or health workers to distribute the drugs (and generally
at a small scale) [30, 31, 37].
Integration (economies of scope) and economies of scale
As discussed above, many of the reported costs were for
control programmes targeting more than one NTD, or
deworming integrated within other control programmes
(such as vitamin A supplementation campaigns)
(Table 1). It was not always possible to separate out the
costs for treating STH, making it difficult to compare
the reported costs of different STH treatment strategies.
Evans et al. [20] and Leslie et al. [27], found that inte-
grating PCT programmes across the NTDs produced
economies of scope (Box 1), reducing the overall cost by
16 % to 40 % (this is a comparison of the overall cost of
an integrated programme versus the total cost of using
separate vertical programmes). This highlights the crit-
ical need to consider the local context of the NTD con-
trol programmes when comparing the reported costs of
MDA, or when using the costs for subsequent cost-
effectiveness analysis.
Two studies [20, 24] observed that the cost per treat-
ment notably decreased with increasing numbers treated
Fig. 3 Distribution of the published costing studies over time stratified by the method of distribution. School-based delivery systems were defined as
those utilising teachers and other school officials (not just distributing the drugs at the school). A combination strategy was defined as those using
both the school system and community drug distributers (CDDs)
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i.e. economies of scale (Fig. 5). This occurs because
some of the costs associated with MDA delivery are
fixed (i.e. do not depend on the number treated), and
therefore increasing the number treated reduces the
average fixed cost per treatment. These economies of
scale may account for a notable degree of the observed
variation in the delivery costs of STH treatment (Table 1)
and need to be carefully considered when comparing the
costs of different strategies [24, 38]. For example, the
economies of scale associated with school-based treatment
programmes will likely be notably different to those of
programmes using mobile teams (which would probably
have a higher variable cost per treatment (Box 1)).
Adopted costing perspective
The perspective of the analysis determines which costs
are included i.e. the patients, service providers or the so-
ciety as a whole. In the majority of the studies the per-
spective was not explicitly stated (or justified), though it
was possible to infer from which costs were included
Fig. 4 The number of identified costs for STH control, stratified by treatment frequency and the method of distribution. School-based delivery
systems were defined as those utilising teachers and other school officials (not just distributing the drugs at the school). A combination strategy
was defined as those using both the school system and community drug distributers (CDDs). Studies that just reported the costs of one treatment
round were classed as annual. Some studies were counted more than once as the treatment frequency was varied within the study
Fig. 5 Observed economies of scale associated with mass drug administration (MDA). Data from a: Brooker et al. [24], b: Evans et al. [20]
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that in almost all of the studies the perspective used was
that of the service provider i.e. the control programme.
One study [29] was found that collected costs from the
perspective of the families (payers) – in this case only
the cost of the drug was reported as being relevant,
which may not be generalisable to settings where pa-
tients have to travel to get access to treatment.
Issues of time (annualisation and discounting)
There where notable inconsistencies in whether or not
studies annualised the costs of capital resources; this is
the process whereby the gross cost of capital resources
(i.e. those which last longer than a year) are spread over
their average useful lifetime, to arrive at an average
yearly cost. This may produce a disparity in the reported
costs between different studies, particularly for control
programmes in their first year, when many of the capital
resources will be purchased. Furthermore, assumptions
regarding the useful lifetime of capital resources and the
discount rate used were rarely stated or subjected to
sensitivity analysis.
Drug costs
We observed a notable variation in the reported drug
costs between the different studies (Table 1). This is in
part because the drugs have become cheaper over time
[39], at times were donated (and therefore would only be
included in the full economic cost), and due to variations
in which other drugs were administered/purchased within
the same programme. A more in-depth description of the
drug costs and how they have changed over time is pre-
sented in [39]. More recently Montresor et al. [40] esti-
mated the median price for a container of 1,000 tablets of
albendazole (400 mg) was US$18.1 (range US$15.1–28),
giving an average unit cost of US$0.018. A similar cost
was estimated for mebendazole (500 mg) with the median
price for a container of 1,000 tablets being US$19.1 (range
US$11.9–27.6). The cost of international transport and
custom clearance has been estimated to be an additional
10 % of the total value of the drug [40].
Reported cost-effectiveness of STH treatment
We identified 17 studies that investigated the cost-
effectiveness of STH treatment (Table 2). The majority of
the cost-effectiveness estimates pertained to interventions
targeting only SAC; which were mostly found to be within
the range of being highly cost-effective based on the
World Bank thresholds [41]. Though it should be ac-
knowledged that the methodology and key assumptions
were often unclear, and surrounded by notable uncer-
tainty– particularly for the estimates in terms of US$ per
DALY averted [42, 43].
We identified only seven studies exploring the
cost-effectiveness of alternative treatment strategies
[21, 29–32, 44, 45]: four of which used mobile teams
(Table 2). A summary of aim, method and primary
conclusions of the identified studies is presented in
Table 2 – which have generally been replaced by school/
community-based delivery systems (Fig. 3).
It should be noted that for several of the reported
cost-effectiveness estimates, the method of distribution
and treatment frequency were not clearly stated and
many did not employ any (or any detailed) sensitivity
analysis. This lack of clarity, and at times poor quality, is
not exclusive to STH, but has been found to be common
in economic evaluations for parasitic diseases [46].
Adopted cost-effectiveness perspective
As with the cost studies discussed above, the clear
majority of the cost-effectiveness studies were conducted
from the perspective of the service provider i.e. the con-
trol programme (again this was rarely explicitly stated or
justified). Only one cost-effectiveness analysis was found
that used a societal perspective [47], and one the family’s
(payer’s) perspective [29].
Choice of effectiveness measure
A variety of different effectiveness outputs were used for
these analyses; such as egg reduction, infection cases
averted, heavy cases averted and reduction in anaemia
(Table 2). This variety in outcome metrics makes it diffi-
cult to compare the results of the different studies.
Due to the difficulties in developing statistical models
linking the population dynamics of the STH to the inci-
dence of different disease outcomes, most of the model-
ling studies used infection-based effectiveness metrics
(i.e. reduction in mean worm burden (Table 2)). These
studies defined disease as having a modelled worm bur-
den above a certain threshold [21, 44, 45]. Only two
modelling studies [47, 48] were found that used DALYs
as the effect measure.
Sources of cost data
We found that over a third of the identified cost-
effectiveness analyses used costs associated with treat-
ment distribution via mobile teams (Table 2 and Fig. 6),
which have now mostly been replaced by school/com-
munity-based delivery systems (Fig. 3). Furthermore,
many of the studies that did investigate school-based de-
livery programmes used costs (at least in part), based on
the results of two Partnership for Childhood Develop-
ment (PCD) studies [16, 17]. However, these results have
been identified as potentially being artificially low
because they did not include the external costs of the
UK-based coordinating centre [39]. Several studies were
found that used unpublished cost data (Table 2).
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Table 2 Summary of the identified cost-effectiveness estimates
Study Question Target of
intervention
Target age group/ primary distribution
method/ treatment frequency
Effects Primary conclusions Source of the costs
Empirical
studies
[29] Cost-effectiveness of albendazole
for preventing stunting in Pre-SAC.
STH (primarily
Ascaris)
• Pre-SAC • Prevention of stunting Six monthly albendazole
reduces the risk of stunting
in Pre-SAC with only a
small increase in the
expenditure on health
care from the payer’s
perspective (₹543 Indian
Rupees for each case of
stunting prevented).
Same study
• Mobile teams
• Biannual (six monthly)
[24] Cost-effectiveness of nationwide
school-based helminth control
in Uganda.
STH and
Schistosomiasis
• SAC • Anaemia cases averted The cost per anaemia case averted was
estimated to range from US$1.70–9.51
(depending on the number treated
within the different districts (see
Table 1)).
Same study
• School-based treatment
• Annual
[30] The cost-effectiveness (and cost-
benefit) of a project administering
deworming and weekly iron-folic
acid supplementation to control an-
aemia in women of child-bearing
age.
STH and
weekly iron
supplements
• Women of child-bearing age • Anaemia cases averted The cost per anaemia case averted was
estimated to be US$4.24.
Same study
• Village health workers • A cost benefit ratio
based on the labour
market productivity for
women of reproductive
age after removal from
anaemia
The benefit: cost ratio was estimated to
be 6.70:1, i.e. for each dollar invested in
the weekly iron supplementation and
deworming program the monetary value
in terms of productivity was US$6.70.
• Treatment every four months in the
first year and every six months
thereafter.
[79] Cost-effectiveness of school-based
anthelmintic treatments against
anaemia in children.
STH and
Schistosomiasis
• SAC • Anaemia cases averted The cost per anaemia case averted by
deworming school children was in the
range of US$6–8.
[17]
• School-based treatment
• Annual
[31] Comparison of mass, targeted and
selective chemotherapy with
levamisole for Ascaris control.
Ascaris • Varied (selective, targeted (to Pre-SAC
and SAC), and mass)
• Egg reduction per gram
of faeces
The mass and targeted treatment
strategies were considerably more cost-
effective then selective treatment.
Same study
• Mobile teams Cost per 1000 egg reduction per gram of
faeces:
• Three monthly • Selective treatment: ₦5,004,
• Targeted treatment: ₦611,
• Mass treatment: ₦451.
[26] Cost-effectiveness of school-based
and community distributed
chemotherapy for schistosomiasis
and STH control.
STH and
Schistosomiasis
• SAC and targeted adults • Infections averted The estimated cost per infection averted
in the treated population (children and
adults) was US$2.50.
Same study
• Combination
• Annual
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Table 2 Summary of the identified cost-effectiveness estimates (Continued)
[32] The cost-effectiveness of selective
health interventions for the control
of STH in rural Bangladesh.
STH • Varied (See Table 1) • Reduction of mean egg
counts
A single round of albendazole to all
household members (over the
18 month study) was more
cost-effective than chemotherapy to all
household members followed by
subsequent six monthly chemotherapy
to all children. The two regimens
involving health education were the
least cost-effective.
Same study
• Mobile teams • Reduction in prevalence
• Varied (one round over 18 months vs
six monthly)
[73] Cost-effectiveness (and cost-benefit)
of school-based STH and
Schistosomiasis control.
STH and
Schistosomiasis
• SAC • DALY Treating SAC is highly cost-effective –
US$5 per DALY averted (it was noted
that this estimate ignores the indirect
benefits for untreated children and adults
in the treatment area). Though in areas
without schistosomiasis, the cost per
DALY averted was estimated to be
US$280 – discussed in [42].
[16]
• School-based treatment • Additional years of
school participation
The cost per additional year of school
participation was estimated to be
US$3.50 and deworming was found to
increase the net present value of wages
by over US$30 per treated child.
• Biannual albendazole (annual
praziquantel)
• Net present value of
wages
[80] Effects of the Zanzibar school-based
deworming program on iron status
of children.
STH and
Schistosomiasis
• SAC • Anaemia cases averted The cost per moderate to severe
anaemia case (Hb < 90 g/L) averted over
one year (with four monthly
mebendazole treatment) was US$3.57,
increasing to US$16.30 for the cost per
severe anaemia averted (<70 g/L).
Unpublished data
• School-based treatment
• Four monthly
Modelling
(type of
model –
see Box 2)
[48] Cost-effectiveness of school-based
Ascaris control (dynamic model).
Ascaris • SAC • DALY The analysis indicates that treating SAC is
highly cost-effective; US$8 per DALY
averted (for a high prevalence
community).
Unpublished data
• School-based treatment
• Annual
[21] Cost-effectiveness analysis of mass
anthelmintic treatment: effects of
treatment frequency on Ascaris
infection (dynamic model).
Ascaris • Mass treatment (i.e. all three age
groups)
• Unit reductions in mean
worm burden
If the aim of an intervention is to reduce
Ascaris related morbidity using mass
treatment, then it is more cost-effective
to intervene in higher transmission areas.
Furthermore, relatively long intervals
between treatments offer the most cost-
effective strategy.
Unpublished data
• Mobile teams • Infection cases averted
• Varied (between every four months
and every two years)
• Disease cases averted
[44] Options for chemotherapeutic
control of Ascaris (dynamic model).
Ascaris • Varied (mass vs, targeted (to SAC and
Pre-SAC))
• Infection cases averted Child-targeted treatment can be more
cost-effective than mass treatment in
reducing the number of disease cases.
The results also imply that (with the
assumed circumstances) enhancing
[21] – which was
based on
unpublished data
• Mobile teams • Disease cases averted
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Table 2 Summary of the identified cost-effectiveness estimates (Continued)
coverage is more cost-effective than
increasing frequency of treatment.
• Varied (between every six months and
every two years)
[45] The cost-effectiveness of using dif
ferent thresholds for determining
the treatment frequency (static
distribution model).
STH • Pre-SAC and SAC • Cost per infected
person treated
This analysis suggests that a new
three-tier treatment for deciding initial
treatment frequency (if the combined
prevalence is above 40 %, treat all
children once a year; above 60 % treat
twice a year; and above 80 % treat three
times a year), would be more
cost-effective than the current WHO
recommended thresholds.
[16, 17, 22, 24]
• Combination of school-based
treatment and Child Health Days
• Cost per moderately/
heavily infected person
treated,
• Varied at different thresholds • Cost per diseased
person treated
[47] The potential cost-effectiveness of a
hookworm vaccine (static model).
Hookworm • SAC and non-pregnant women of
child-bearing age
• DALY A hookworm vaccine may provide not
only cost savings, but potential health
benefits to both SAC and non-pregnant
women of child-bearing age. The most
cost-effective strategy may be to
combine vaccination with the current
drug treatment.
[4, 39, 81]
• Combination of school-based
treatment and CDDs
• Annual
Policy
documents/
reports
[4] Cost-effectiveness of school-based
STH control.
STH ±
Schistosomiasis
• SAC • DALY This analysis indicates that treating SAC is
highly cost-effective; US$3.41 per DALY
averted. (In combination with praziquan-
tel to treat schistosomiasis this changes
to US$8–19 per DALY averted.)
Not clearly stated
• School-based treatment Though it should be acknowledged that
this estimate was found contain a number
of errors [43]. GiveWell re- estimated the
cost-effectiveness (using a different meth-
odology) and obtained US$30–$80 per
DALY averted [43].
• Annual
[34] Cost-effectiveness of treating SAC
for STH and schistosomiasis.
STH and
Schistosomiasis
• SAC • DALY This analysis indicates that treating SAC is
within the range of being considered
highly cost-effective; US$6–33 per DALY
averted.
Unpublished data
• Mobile teams (via the school)
• Annual
[41] Cost-effectiveness of treating SAC. Not clear • SAC • DALY This analysis indicates that treating SAC is
within the range of being considered
highly cost-effective; US$15–30 per DALY
averted.
Not clearly stated
• Not clear
• Not clear
More detailed information regarding the costs (when available) is provided in Table 1. CDDs; Community drug distributers, Pre-SAC; Pre-school aged children, SAC; School-aged children. School-based delivery systems
were defined as those utilising teachers and other school officials (not just distributing the drugs at the school)
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Type of method
Mathematical models can be particularly useful tools for
investigating the cost-effectiveness of alternative STH
treatment strategies and quantifying the impact of dif-
ferent epidemiological and programmatic settings on
the generalisability of the conclusions. Furthermore,
models can be used to make projections over long time
horizons, capturing the long term benefits of interven-
tions (empirical/data driven approaches using primary
data from the field often have a limited time horizon of
a few years and frequently only occur in one setting).
However, only two studies [21, 44] were identified that
investigated the cost-effectiveness of alternative STH
treatment strategies using a dynamic model (the differ-
ences between dynamic and static models are defined
Box 2) [49]. These studies only focused on Ascaris, and
consequently the potential influence of the other STHs
on the cost-effectiveness of different strategies was not
explored. This is particularly important for hookworm,
which has a notably different age-profile of infection
than Ascaris, with the adults usually having a larger pro-
portion of the overall worm burden [13]. Consequently,
ignoring this aspect may underestimate the value of
expanding MDA programmes to target the whole com-
munity. Furthermore, the costs used in these studies
[21, 44] were based on the use of mobile teams (the
main delivery method at the time) in Africa. The effect
the use of the current school/community-based delivery
systems has on the modelling conclusions has not been
subsequently considered.
Box 2: Model types
Fig. 6 The number of identified cost-effectiveness estimates of STH control, stratified by target population and method of distribution. Pre-SAC;
Pre-school aged children, SAC; School aged children. School-based delivery systems were defined as those utilising teachers and other school
officials (not just distributing the drugs at the school). A combination strategy was defined as using both the school system and community drug
distributers (CDDs). Some studies were counted more than once as the target population was varied within the study. *Targeted adults (such as
those in at risk occupations)
Static models: Static models are very widely used in economic
evaluations but assume that the rate at which individual hosts
acquire infection (the force of infection) is uncoupled from the
abundance of infection in the population [49] i.e. they assume that
an individual’s probability of being exposed to an infection is
unaffected by an intervention (even if the abundance of infection is
reduced) [50–52].
Dynamic models: Dynamic transmission models couple the rate of
infection and the abundance of infection within the population (in
this case eggs in the environment). Consequently, within these
models the rate of infection changes if the level of infection is
reduced due to an intervention [49–52]. These models therefore
account for the fact that drug treatment programmes targeting
STH will often not only benefit the individuals treated, but also
reduce the risk of infection to others in the population (as the rate
of transmission is reduced). This is particularly important to account
for when investigating which age-groups should be targeted for
treatment. It is also important to note that for the macroparasites
(such as the STH) a dynamic model is also essential to account for
the density dependent processes [53–56] which govern their
transmission; such processes can lead to a highly non-linear impact
of control against transmission [49].
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Discussion
Limitations
A potential source of bias of the employed search strategy
is that it would not retrieve cost and cost-effectiveness esti-
mates that are not within the searched electronic databases
(such as policy documents/reports etc.). To minimise this,
references of the identified studies were searched and key
members of the field were contacted regarding any unpub-
lished data. Furthermore, it should be noted that the selec-
tion of studies was not performed in duplicate.
Knowledge and research gaps
As our analysis of the published literature demonstrates,
the quality and quantity of studies addressing the
current policy decisions in STH control is low (Tables 1
and 2). We therefore highlight policy relevant areas
which will require new research to address.
Costs of different treatment strategies
The majority of the identified costs were for pro-
grammes targeting only SAC (Fig. 2). There are very few
studies reporting the costs associated with treatment
strategies targeting multiple age groups (Pre-SAC, SAC
and adults) within the context of the current school/
community-based delivery systems. This is despite scal-
ing up treatment for both Pre-SAC and SAC currently
being the primary goal for STH control within the
London Declaration on NTDs [6, 7]. Furthermore, in
spite of biannual MDA being recommended by the
WHO in areas with intense transmission/high preva-
lence [1], we found only two studies that reported the
associated costs within a school-based programme
(Fig. 4); both of which did not report the full economic
costs [35, 36]. Detailed investigation of how the costs of
increasing the treatment frequency change in different
settings is vital, as it is unlikely to be simply double the
cost of annual treatment [35, 36, 57, 58]. This lack of
data is further highlighted when looking at the costs
used in the identified cost-effectiveness analyses – with
the clear majority of studies relating to interventions tar-
geting only SAC and most of the few alternatives per-
taining to the use of mobile teams (Fig. 6). However, the
latter have now mostly been replaced by school/commu-
nity-based delivery systems (Fig. 3).
Furthermore, a greater understanding of the economic
value of the STH drug donation programmes, and how
these may be influenced by any change in treatment
strategy, is required.
Economies of scale
Comprehensive costing functions that can account for
how the costs of STH treatment change with the num-
ber treated are essential for estimating the costs of
scaling-up programmes (Fig. 5). Such economies of scale
have also been reported by Goldman et al. [59] regarding
the costs of MDA for LF control.
These economies of scale have been found to have signifi-
cant implications when investigating the cost-effectiveness
of STH control [Turner HC, Truscott, JE, Fleming, FM,
Hollingsworth TD, Brooker SJ, and Anderson, RM: Is scal-
ing up mass drug administration for the control of the soil-
transmitted helminths cost-effective? Submitted] and need
to be carefully considered when comparing the relative
costs of different strategies (particularly between different
studies/settings) [38]. Additionally, the relative increase in
costs for adopting a new strategy (such as increasing the
treatment frequency or expanding to target more age
groups), will likely change depending on the scale of which
it is adopted within a district. Understanding these interac-
tions will be essential to best inform practical policy deci-
sions [60].
Data collection and analysis methods
There is a growing need for standardised tools for costing
data collection to allow for valid comparison between dif-
ferent studies.
Based on our analysis of the current STH costing stud-
ies (Table 1) and those presented in a review of the cost
and cost-effectiveness of insecticide-treated nets [61], we
present an outline of our recommendations for collecting
and presenting STH treatment cost results in Table 3.
In particular, clarity and consistency in the methods
used to handle the pooled costs of shared activities be-
tween different strategies/other control programmes is
needed, particularly as NTD control programmes become
more integrated. It is important that any adjustments to
the data are made clear to allow for valid comparison be-
tween different studies, especially if these costs are to be
incorporated into any cost-effectiveness analysis. Further-
more, there is variation in the methods used to apply an
economic value to the donated time of community volun-
teers and teachers for NTD control [57].
Standardised costing collection and analysis methods
will be a crucial step in identifying the real underlying
drivers of variation in treatment costs.
Understanding drivers of variation in delivery costs
Since it would be impossible to run research studies in
every setting, it is essential the field gains a more general
understanding of the factors that drive the variation in
MDA delivery costs between different countries/health
systems. For example, the STH control programmes in
Asia were more likely to use a “sibling approach” to
reach un-enrolled SAC [62], whereas the African pro-
grammes were more likely to use CDDs. This may influ-
ence the method, and hence the cost, as well as the
achieved coverage of expanding programmes to target
Pre-SAC and/or adults. Furthermore, a school-based
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programme that has a relatively high delivery cost, may
have a lower incremental cost of expanding to incorpor-
ate adults due to the baseline investment in training and
recruitment. Understanding how the structure of differ-
ent health systems may influence the relative costs of
adopting different strategies will be vital to further inves-
tigate what the most cost-effective control strategies are
in different areas.
Sensitivity analyses must be performed in any model-
ling study in order to investigate the robustness and
generalisability of the conclusions to other settings. As
part of this, the structure of the health systems and the
potential difference in the relative costs of new strategies
needs to be considered in economic modelling studies.
This is currently almost never done for STH control, yet
may be very influential in terms of what the optimum
strategy is in a given area and the generalisability of
modelling conclusions. This further highlights the need
for widespread costing studies in a range of areas and
the investigation of the key drivers of the costs.
Table 3 Recommendations for collecting and presenting cost results (based on [61])
Perspective • The perspective of the analysis (which determines whose costs are included) should be clearly stated and
justification provided.
• For STH treatment programmes the costs of accessing treatment are normally negligible and therefore we
recommend the use of a service provider’s perspective. However, if other interventions are also used (such as WASH)
which may incur patient level costs the use of a societal perspective should be considered.
Output • The results should clearly state the treatment frequency, target age group(s), method(s) of distribution and the
reported coverage (stratified by age groups and treatment method).
• For cost-effectiveness studies, the effectiveness metric(s) (such as cost per child treated, cost per health outcome
averted) should be clearly stated and justified.
Resource identification • Include the economic value of the time volunteered by teachers/community drug distributors (CDDs) and donated
items: their time should be valued as the equivalent to their occupation had they not been volunteering calculated
using local pay scales.
• Exclude research costs.
• Include relevant overheads of collaborating organizations (e.g. non-governmental organizations (NGO)
contributions).
• Clarify what management capacity is assumed to exist and whether the study is calculating an average cost of a
programme or an incremental cost of adding an additional intervention within existing programme.
Resource measurement and
valuation
• Where appropriate, account for integrated NTD control activities and shared resources between other control
programmes, thereby indicating economies of scope.
• For all capital items a discount rate of 3 % should be applied-to be consistent with the rate used by the World Bank
[41]. This use of different discount rates (such as country-specific estimates) should be explored in the sensitivity
analysis.
Sensitivity analysis • To reflect the uncertainty in measurements a sensitivity analysis should be carried out on the main factors,
including: discount rate, useful life of capital items, staff costs, fuel costs, and method used to value volunteers’ time.
• Where it is necessary to estimate a share of resources contributed from other programmes or interventions
(particularly in the context of integrated NTD control), the assumptions used should be subjected to sensitivity
analysis.
Reporting of results • Cost estimates should be provided in US$ and adjusted for inflation.
• The cost year and exchange rates should be clearly stated.
• Clearly state whether costs are per treatment round or costs per year.
• Clearly state how the drugs were distributed (i.e. through schools by teachers and/or by CDD) and the number
treated by each method stratified by age and school enrolment status (i.e. indicate how may school-aged children
were treated by the CDD).
• Where possible indicate which costs were fixed and which variable.
• Provide costs stratified by individual programme activities (e.g. programme running costs, community sensitization,
training, drug distribution and treatment, monitoring and evaluation).
• Provide costs stratified by resource type (e.g. personal, equipment, supplies, transportation and facilities).
• Report both the per capita total cost per treatment and delivery cost per treatment (as well as drug costs).
• Report the economic cost both with and without the value of donated drugs.
• Report the number treated each round (and coverage).
• When investigating more than one control strategy, details of how the costs/values of different programmatic
activates were different should be provided and how shared costs have been attributed.
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Consequences of integration
A notable research gap is the lack of understanding re-
garding the costs of integrated NTD control [63, 64] and
how integration may influence the costs of implement-
ing different control strategies (economies of scope).
Furthermore, the implications for STH of LF-related
MDA being halted, leaving these areas at a potentially
increased risk of STH recrudescence need to be evalu-
ated. In contrast, the potential additional benefit of bian-
nual MDA, which is being considered for LF control
[58], could have large benefits for STH which are yet to
be evaluated.
Effectiveness metrics
A notable research gap is the lack of clearly defined met-
rics to evaluate the impact of STH interventions, par-
ticular in terms of morbidity [65]. At present the easily
measurable metrics in the field are the intensity and
prevalence of infection (both measured indirectly by egg
output in faeces). However, the level of egg output per
worm can vary in different areas around the world [53],
highlighting the difficulty in translating number of eggs
to the number of worms.
A debate is needed amongst the NTD research field
regarding what effectiveness measure is best, and feas-
ible to acquire in quantitative studies. The imprimatur
of WHO in such debates to define the best metrics is de-
sirable. This would allow future studies to adopt a com-
mon metric/design structure. It will also be important to
consider how different programmatic aims (such as mor-
bidity control versus reductions in transmission), may
require different effectiveness metrics, as this will affect
the optimum strategy [66].
More research is needed to develop study designs and
statistical methods that relate the disease burden of STH
to experience of infection [67], and to link these disease
frameworks into dynamic transmission models. However,
the relationship between STH infections and disease is
complex, and likely depends on a number of host specific
factors – such as age, time infected, and underlying nutri-
tional status [68]. Consequently, thresholds of infection
intensify above which individuals are said to suffer from
disease (as used as an effectiveness measure in some mod-
elling studies), need to be treated with caution.
DALYs are often used to measure the overall burden
of a particular disease (and are the primary metric used
by the global burden of disease studies [69]). However,
the design of the DALY contains inherent flaws that fail
to acknowledge the implications of context on the burden
of disease for the poor [70]. This results in the significant
underestimation of the disability weights for the NTDs,
which are most prevalent in poor populations [70]. There
is a growing need for the further development of more
comprehensive disability metrics for NTDs (such as the
quality-adjusted life year (QALY)) which can more ef-
fectively capture the disease burden of STH infections
and better evaluate the cost-effectiveness of different
control strategies [71, 72]. Any studies using DALYs or
QALYs as their effectiveness metric should clearly de-
scribe the methodology used to estimate them (and
highlight the potential limitations and uncertainties of
the estimates).
It is also important to consider the non-health re-
lated benefits of deworming [60] – such as on educa-
tion, and capital development (as discussed by Miguel
and Kremer [73]).
Conclusions
In this time of rapidly expanding MDA coverage and the
new commitments for STH control it is essential that re-
sources are allocated in an efficient manner to have the
greatest impact. The majority of the identified cost-
effectiveness analyses for STH treatment pertained to
programmes targeting only SAC, with relatively few
studies exploring the cost or cost-effectiveness of alter-
native strategies. The optimum treatment strategy in
terms of targeting of different age-groups, or frequency
of treatment, has been shown to be highly specific to the
local epidemiology [8–10]. Consequently, in some areas
(particularly those with high transmission) it may be
more cost-effective or even cost saving to initially use
more expensive but intensive interventions—such as
expanding to treat other age groups—in order to reduce
programme duration and the overall net cost of the con-
trol. Detailed and accurate costs of targeting different
combinations of age groups or increasing the treatment
frequency will be essential to permit further evaluation
of the most cost-effective control strategies.
Due to the inconsistences in the collection/analysis
methods used in published STH costing studies, it is not
possible to draw firm conclusions regarding the relative
costs of the different strategies. This inconsistency,
coupled with a significant lack of data, constitutes a
major research gap in for the optimization of STH control.
However, there are numerous opportunities to collect
these data as programmes are scaled-up, and whilst
lymphatic filariasis programmes are still operating at scale.
With suitable guidance, countries could collect locally
relevant information which could guide the long-term in-
vestment in these programmes over the coming years. We
present an outline of our recommendations for collecting
and presenting STH treatment cost results in Table 3.
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